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Aims. The prognostic role of the proteases uPA and PAI-1, as well as tumor budding, in colon cancer, has been investigated
previously.Methods.Weprovide 6-year follow-updata and results of the validation set.The initial test set and validation set consisted
of 55 colon cancers and 68 colorectal cancers, respectively. Tissue samples were analyzed for uPA and PAI-1 using a commercially
available Enzyme-Linked Immunosorbent Assay (ELISA). Tumor budding was analyzed on cytokeratin-stained slides. Survival
analyses were performed using cut-offs that were determined previously. Results. uPA was not prognostic for outcome. PAI-
1 showed a trend towards reduced cancer specific survival in PAI-1 high-grade cases (68 versus 83 months; 𝑃 = 0.091). The
combination of high-grade PAI-1 and tumor budding was associated with significantly reduced cancer specific survival (60 versus
83 months; 𝑃 = 0.021). After pooling the data from both sets, multivariate analyses revealed that the factors pN-stage, V-stage, and
a combination of tumor budding and PAI-1 were independently prognostic for the association with distant metastases.Conclusions.
A synergistic adverse effect of PAI-1 and tumor budding in uni- and multivariable analyses was found. PAI-1 could serve as a target
for anticancer therapy.
1. Introduction
The role of the microenvironment in cancer has recently
gained growing attention. Different conditions can inhibit
or enhance tumor growth and dissemination. For exam-
ple, tumor-associated inflammatory reactions can induce
tumor inhibition or promotion. Bioactive molecules released
from inflammatory cells to the microenvironment support
different hallmark capabilities, including proliferation, cell
death limitation, angiogenesis, and matrix modification [1].
Because of its central role in tumor progression, different
elements of the microenvironment, such as angiogenesis and
the t-cell response, have been identified as interesting targets
for anticancer therapy [2]. These general concepts are also
valid for colorectal cancer, which is the third leading cause
of cancer in the US, with an estimated incidence of approx-
imately 132,000 cases in 2016 [3]. The plasmin/plasminogen
system plays an important role in the interaction between the
tumor and its matrix. This system consists of the urokinase
plasminogen activator (uPA), cell surface receptor urokinase
plasminogen activator (uPAR), and its inhibitors plasmino-
gen activator inhibitors 1 and 2 (PAI-1 and PAI-2). UPA and
PAI-1 are known to be predictors of aggressive behavior in
breast cancer and have been recommended for the diagnosis
of node negative breast cancers since 2007. Between 2007
and 2008 our group investigated the potential prognostic
value of an ELISA-based uPA and PAI-1 evaluation in
colon cancer. Moreover, we assumed that tumor budding, as
the histomorphological correlate of epithelial-mesenchymal-
transition (EMT), was also associated with the activity of
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the plasmin/plasminogen system. In this previous study, we
found a strong association between elevated uPA levels and
tumor budding, as well as high-grade histology. PAI-1 was
predictive of distant metastases [4]. We now provide a 6-year
follow-up. Additionally, we evaluated another set of cases to
validate the findings from the previous study. A subset of
rectal cancers was included to estimate whether the findings
in these locations were similar to those in colon cancer.
2. Materials and Methods
2.1. Patients and Specimen Preparation. The test set has been
described before. In brief, it consists of 59 colon specimens
with 55 cancer lesions that were collected between August
2007 and September 2008. Follow-up data were provided
by the clinical and population-based cancer registry of
Augsburg, Augsburg, Germany. Additional information was
retrieved from the files of the Institute of Pathology and
the clinic information system. The physicians that were
responsible for further care were contacted to gain informa-
tion, especially concerning disease control or progression.
This study was approved by the ethical committee of the
Landesärztekammer Bayern. Informed and written consent
was obtained from all patients.
The 68 colorectal cancer cases of the validation set were
collected between April and November 2014. This study
was approved by the internal review board of the Klinikum
Augsburg on the basis of the recommendation by the ethi-
cal committee of Landesärztekammer Bayern regarding the
previous study. The inclusion criteria for this study were
established or suspected colorectal cancer and an elective
oncological resection. Emergency surgery or noncurative
intentions were criteria for exclusion.
The specimen preparation has been described before. In
brief, a 1 cm3 tissue block was cut from the invasive tumor
region in the fresh tissue immediately after receiving the
unfixed specimen. The time between resection and sample
collection was less than 30 minutes. In 13 cases from the test
set, samples from nonneoplastic regions were also collected.
The samples were stored at −20∘C for a maximum of 14 days
before performing ELISA. Malignancy and the estimation of
proportion of the neoplastic cells in 10% stepswere confirmed
by H&E histology in all samples for the ELISA.
2.2. Laboratory Assay. A commercially available ELISA kit
for uPA and PAI-1 that is certified for usage in breast
cancer was used (Femtelle Test (EF 899), Sekisui Diagnostics,
Stamford, CT). The test was conducted according to the
protocol recommended by the manufacturer and has been
described before [4]. In brief, frozen tissue samples were
disrupted by mechanical force under permanent cooling.
Tri-Buffer, supplemented with the nonionic detergent Triton
X-100, was used to extract the tumor cell cytosol. The
suspensionswere centrifuged to separate the soluble fractions
from the cell debris. The total protein concentrations of
the cytosolic fractions were measured. On day 2, a diluted
tissue extract was added to antibody-coated microwells and
incubated overnight. On day 3, detection antibodies were
added and incubated. After another incubation step with the
enzyme conjugates, the reactions were stopped with 0.5M
H2SO4 and the absorption of the solutionwasmeasured using
a microwell reader at 450 nm. The levels of uPA and PAI-
1 were expressed in nanograms per milligram (ng/mg) of
tumor protein. Based on the evaluation of the test set [4]
the cut-off values for uPA and PAI-1 were ≥4 ng/mg and
≥40 ng/mg, respectively, to discriminate between low and
high-grade levels.
2.3. Tumor Budding and Immunohistochemistry. Tumor bud-
ding was defined as isolated tumor cells or clusters of up
to four cells at the invasion front according to Ueno et al.
Because of the usage of a microscope with an eyepiece with
a field number of 25, the cut-off for high-grade budding was
adjusted to ≥30 buds/20-fold magnification in comparison to
the original publication [15]. The evaluation was performed
on slides that were immunohistochemically stained for pan-
cytokeratin to enhance the detectability of single cells. All
reactions were performed using a Ventana Benchmark Ultra
system. Cell Conditioning Solution (CC1) (Ventana - Roche
Diagnostics, Mannheim Germany) was used at the pretreat-
ment step during the processing of all sections.Thediagnostic
antibody against keratin KL1 (mouse, monoclonal, 1 : 100)
was provided by Medac, Wedel, Germany. Independent eval-
uations were performed by two pathologists (Bruno Märkl
and Tina Schaller). In cases of a discrepancy concerning the
discrimination between no/low tumor budding and high-
grade tumor budding, a consensus decision was made using
a double-headed microscope.
Immunohistochemistry for the mismatch repair proteins
PMS2 and MSH6 was performed to determine the mismatch
repair status in the cases of the validation set where eval-
uations concerning microsatellite instability (MSI) and/or
mismatch repair deficiency (MMRd) have not been per-
formed in the frame of the routine diagnostic. The following
diagnostic antibodies were used: PMS2 (Clone EP51, ready
to use,) (Clone EP49, ready to use). All reactions were
developed using the Ventana Ultravision detection system
(Roche Diagnostics, Mannheim, Germany).
2.4. Statistical Analysis. The Mann–Whitney Rank Sum test
was used to compare numeric values. Correlations were
calculated with Pearson Product Correlation. Tabulated data
were compared using the𝜒2 test or Fisher’s Exact test depend-
ing on the number of observations. Backward stepwise
logistic regression analysis was used to identify independent
predictors of metastatic disease. For the survival analysis,
Kaplan-Meier Curves were calculated and differences were
analyzed with the Log-Rank test. The mean survival times
were calculated because the median survival was not reached
inmost analyses. For the determination of themedian follow-
up time, the method of Schemper and Smith was used. The
Cox regression proportional hazards model was used for the
multivariate analysis of cancer specific analysis. The Cohens-
Kappa value was calculated to evaluate the interobserver
variability during the tumor budding evaluation. All calcu-
lations were performed using the Sigma Plot 13.0 software
package (Systat, Richmond, VA, USA). 𝑃 values < 0.05 were
considered significant.
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Mean age ± SD 71 ± 13 68 ± 8
Gender (m : f) 0.57 : 1 0.33 : 1
Right colon 19 3
Left colon 36 1
Conventional histological type 48 /
Mucinous type 4 /
Medullary type 1 /
Micropapillary type 2 /
Infiltrative invasion type∗ 4 /
pT 1/2 16 /
pT 3/4 39 /
Low/moderate grade 39 /
High grade 16 /
Node positive 21 /
Lymphatic invasion 4 /
Venous invasion 6 /
Perineural invasion 3 /
Strong chronic inflammation 11 /
Metastatic disease 7 /
Mean LN, number ± SD 33 ± 18 19 ± 6
∗Infiltrative type according to Jass. SD, standard deviation; LN, lymphnodes.
3. Results
3.1. Test Set: Patients and Follow-Up. The test set consists of 55
colon cancer cases. Forty-seven of these cases met the criteria
for survival analysis. The basic clinicopathological data have
been described before and are briefly given in Table 1. The
mean and median follow-up times were 75 and 80 months
(95% CI: 76.9–83.1).
3.2. Test Set: Cancer Specific Survival (CSS). Cancer specific
survival was not different in cases with low and high uPA
levels with a mean CSS time of 80 months (95% CI: 70–91)
versus 76 months (95% CI: 59–94) (𝑃 = 0.735), respectively.
However, a clear trend towards adverse outcome was found
for PAI-1. Cases with high PAI-1 levels showed a mean
CSS time of 68 months (95% CI: 47–89) compared to low
PAI-1 level cases with a CSS time of 83 months (95% CI:
74–93) (𝑃 = 0.091). High-grade tumor budding was also
associated with impaired survival, with a mean CSS time of
71 months (95% CI: 53–89) versus 83 months for low-grade
tumor budding (95% CI: 73–33) (𝑃 = 0.187). Although
this difference was not statistically significant, the Kaplan-
Meier curves showed a clear discrimination between the two
groups. After combining the parameters tumor budding and
PAI-1, the cases with no or only a single positive revealed a
significantly higher CCS in comparison to cases that were
positive for both.Themean times for negative/single positive
versus double positive cases were 83 months (95% CI: 74–91)
and 60months (95%CI: 29–91), respectively (𝑃 = 0.021).The
Kaplan-Meier curves are shown in Figure 1. After performing
multivariate analysis including the factors N-stage, vascular
invasion, PAI-1, tumor budding, and the combination of
PAI1 and tumor budding, only N-stage was found to be
independently prognostic. However, the combination of PAI-
1 and tumor budding just failed independence, with a P-for-
Enter of 0.057.
3.3. Validation Set: Patients and Correlations between uPA,
PAI-1, and Tumor Budding. The validation set consists of
68 colorectal cancer cases. The clinicopathological data are
summarized in Table 2. The two investigators of tumor
budding reached a moderate interobserver agreement with a
𝜅-value of 0.48.
All samples contained neoplastic cells. The mean per-
centage of the vital tumor was 640.207 ± 22% (Range 5–
90%). There was a weak nonsignificant association between
the tumor amount and the level of uPA and no association
with PAI-1 (𝑅 = 0.207, 𝑃 = 0.093; 𝑅 = 0.0594, 𝑃 = 633).
The mean uPA and PAI-1 levels were 4.0 ± 2.2 and
38.1 ± 33.7 ng/mg protein. Both parameters showed a strong
correlation (𝑅 = 0.709; 𝑃 < 0.001) with each other. However,
in this set, tumor budding did not correlate significantly with
uPA or PAI-1 (𝑅 = 0.08 and 𝑅 = 0.218) (Figure 2).
3.4. Validation Set: Proteinase Levels and Tumor Budding
according to Other Histopathological Factors. There was no
difference in the uPA and PAI-1 levels when comparing
cases with and without vascular invasion. Additionally, no
difference was found between the uPA levels in node negative
or node positive cases (Figure 3(c)). However, there was a
significant difference between these subgroups regarding the
PAI-1 levels with a median level of 35.5 versus 16.5 ng/mg
protein (𝑃 = 0.043) (Figure 3(d)). The association between
nonconventional histological type and high uPA and PAI-1
values is remarkable, in this context (𝑃 = 0.002; 𝑃 < 0.001).
Further significant differences were found for uPA and PAI-
1 between the different pT-stages (𝑃 = 0.007; 𝑃 < 0.001)
(Figures 3(a) and 3(b)) and grading (𝑃 < 0.001; 𝑃 = 0.007)
(Figures 3(e) and 3(f)). Additionally, a nonsignificant trend
towards higher PAI-1 levels was found in metastatic disease
(𝑃 = 0.153) (Figure 3(h)), whereas the uPA levels showed
no significant differences between localized and metastatic
disease (Figure 3(g)).
The clinicopathological data, stratified according to the
cut-off values for uPA and PAI-1 that were determined during
the first evaluation of the test set, are given along with the
data for tumor budding in Table 2. In brief, there was a clear
trend towards a higher rate of locally advanced cancers (68%
versus 89%; 𝑃 = 0.07) and a significantly higher rate of high-
grade tumors in the uPA-high group (10% versus 39%; 𝑃 =
0.01). Both parameters were also significantly differentially
distributed in the PAI-1 low versus high groups (63% versus
100%; 𝑃 = 0.002 and 50% versus 67%; 𝑃 = 0.01, resp.).
High-grade tumor budding was more highly associated
with male gender (𝑃 = 0.05) and node positivity (50% versus
76%;𝑃 = 0.091). It was also significantly associated with a left
side location (49% versus 65%; 𝑃 = 0.029), venous invasion
(10% versus 65%; 𝑃 = 0.022), and metastatic disease (10%
versus 47%; 𝑃 = 0.002).


























































































Figure 1: Test set: cancer specific survival of (a) uPA, (b) PAI-1, (c) tumor budding, and (d) a combination of tumor budding and PAI-1
(no or one positive versus double positive). Cut-offs: uPA ≥ 4.0 ng/mg protein; PAI-1 ≥ 40 ng/mg protein; tumor budding ≥ 30 buds/20-fold
magnification.
3.5. Pooled Data. After pooling the data from the test and
the validation set, the risk for the occurrence of distant
metastases was calculated for pT-stage, pN-stage, venous
invasion, grading, uPA, PAI-1, tumor budding, and the com-
bination of tumor budding and PAI-1 (Figure 4). Significant
prognostic effects were found for pT-stage, pN-stage, venous
invasion, PAI-1, tumor budding, and the combination of
tumor budding and PAI-1. The corresponding odds ratios
were inf., 30.8, 21.3, 4.1, 6.7 and 13.5, respectively. UPA
just failed to meet significance with 𝑃 = 0.051 (OR: 3.5).
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Grading Y Y Y 𝑁 Y Y Y 𝑁
T-stage 𝑁 Y T 𝑁 Y Y 𝑁 𝑁
N-stage 𝑁 𝑁 𝑁 𝑁 Y 𝑁 Y T
V-stage 𝑁 𝑁 𝑁 Y T 𝑁 𝑁 Y
M-stage Y∗ T T Y∗ T Y Y∗ Y
Y, statistically prognostic; N, not statistically prognostic; T, trend towards prognostic relevance; bold and italic fonts, concordance between test and validation
set; bold italic font, discordance between test and validation set. ∗Evaluation according to cut-off stratification.





















Figure 2: Correlation between tumor budding and uPA and PAI-1.
The multivariate analyses revealed that the factors pN-stage,
venous invasion, and combination of tumor budding and
PAI-1 were independently prognostic for the occurrence of
distant metastases.
4. Discussion
Here, we provide follow-up data from a prospective study that
was initially performed in 2007/2008 to investigate the role
of the serine proteases uPA and PAI-1 in tumor budding in
colon cancer [4]. Moreover, we present the initial data from a
recently performed validation study. The survival analysis of
the test set revealed a nonsignificant trend towards an adverse
outcome for patients with high PAI-1 tissue concentrations
and high-grade tumor budding. The fact that a combination
of both factors leads to a significant discrimination regarding
cancer specific survival can be seen as an indication that
both factors interact and enhance tumor cell migration
and tumor progression. Tumor budding is characterized
by the loss of E-cadherin, a mesenchymal phenotype, and
detachment from neoplastic glands [16–20]. Other authors
have described similar connections between the function of
the plasmin system and tumor budding. Recently, Sánchez-
Tilló et al. reported that ZEP1 regulates uPA and PAI and
is expressed in dedifferentiated cells at the invasion front
that have lost E-cadherin [13]. Minoo et al. found that
immunohistochemical overexpression of uPA and the loss
of E-cadherin and APAF-1 are predictive of the infiltrating
tumor border [7]. Hiendlmeyer et al. found that 𝛽-catenin
upregulates uPA expression. The evaluation of our test set
revealed strong correlations between tumor budding anduPA
and PAI-1 levels [22]. However, in our validation set, we only
found a weak correlation between budding and PAI-1 with
marginal significance.Themedian PAI-1 and uPA levels were
evaluated in cases with high-grade budding. An interesting
finding is that uPA and PAI-1 levels were strongly associated
with the histological type in the validation set. Specifically, the
mucinous typewas significantlymore often found in the uPA-
and PAI-1-high groups. Reevaluating the test set revealed a
trend (𝑃 = 0.167) in this direction.
In our initial study, we showed an association between the
tissue levels of uPA and PAI-1 and aggressive histopathologi-
cal features of colon cancers. The recently finished validation
study confirmed the role of these proteases as negative
prognostic markers in colon cancers. This was true when the
mean values were compared and also when the collectionwas
stratified according to previously determined cut-off values.
However, it has to be stated that the combinations of factors
that were associated with each other were not completely
identical (Table 3), which is very likely influenced by the
relatively small number of cases for these studies, including
all stages of cancers, which is a clear limitation. Another
limitation is that the two studies are not optimally balanced.
The validation study included proportions of right sided,
nodal positive cancers, as well more cases with vascular
invasion and distant metastases, which may have also con-
tributed to the instability found in the results. Nevertheless,
whenever significant differences were found, they indicated
an association of the proteases with aggressive behavior. This
was especially true for PAI-1 and tumor budding.
A multivariable analysis performed after pooling the
data from both sets revealed that pN-stage, V-stage, tumor
budding, and PAI-1 were independently associated with
distant metastases. The prognostic role of PAI-1 in colorectal
cancers has been evaluated by several other groups, and the
Gastroenterology Research and Practice 7
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Figure 3: Validation set: mean tissue levels of uPA and PAI-1 according to pT-stage (a and b), pN-stage (c and d), grading (e and f), and
M-stage (g and h).
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Table 4: Previous studies investigating the prognostic role of uPA and PAI-1 in colorectal cancer.
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stem cells; CR, colorectal. Note: literature from 1993–2008 is given in [4].
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Figure 4: Pooled data: odds ratios of different risk factors for the
associationwith distantmetastases. Note the logarithmic scale of the
𝑋-axis.
overwhelming majority of studies confirmed that PAI-1 is
an adverse factor [4]. An overview of the more recently
published literature is given in Table 4 [6–14]. Wang et
al. performed a meta-analysis to evaluate the influence of
the PAI-1 4G/5G polymorphism. Individuals with a 4G/4G
genotype have increased PAI-1 plasma levels and show an
increased susceptibility to colorectal and endometrial cancer
[23]. Iacoviello et al. also found increased plasma levels of
PAI-1 in patients with colon cancers compared to controls
in a large retrospective analysis [12]. Experimental data came
from Hogan et al. and Chen et al., who show that cancer cell
functions are influenced by PAI-1 [10, 14]. Moreover, Chen et
al. demonstrated compromised tumor growth caused by the
silencing of PAI-1.
In the analyses of the test and validation sets, UPA was
found to be inferior concerning its prognostic significance
in comparison to PAI-1 and tumor budding. Kushlinskii
et al. also found PAI-1, but not uPA, to be prognostic in
colorectal cancer [9]. However, this result is in contrast to
those of other studies that reported strong correlations with
aggressive behaviors, including impaired survival rates [7,
24–29].Most of these studieswere performed using immuno-
histochemistry, which could be a technical explanation for
Gastroenterology Research and Practice 9
this discrepancy. Ganesh et al. and Herszènyi et al. used
ELISA and also reported impressive survival differences [25,
30]. The main difference between their investigations and
ours is that they used a different ELISA. However, it seems
unlikely that this can fully explain this strong discrepancy. It
remains unclear why we could not confirm the data of these
authors.
Tumor budding is gaining recognition as a promising and
robust prognostic factor in colorectal cancer. It is especially
interesting for the evaluation of malignant polyps in the
preoperative setting and in stage II cancers [31]. Its prognostic
relevance in the whole gastrointestinal tract has been investi-
gated in a large number of studies [31, 32]. However, there are
still two main issues with these factors that remain unsolved.
Themost important of these issues is the fact that an accepted
consensus on how tumor budding should be evaluated is
lacking. The other point is the relatively weak interobserver
agreement, at least in some of the publications [32]. Puppa
et al. found a fair agreement between the international par-
ticipants of their study. Cytokeratin immunohistochemistry
improved the agreement [33]. In our study, we also achieved
only moderate interobserver agreement, with a 𝜅-value of
0.48. It is astonishing that, despite these limitations, tumor
budding has been demonstrated to be a robust adverse factor
many times. An increased risk for lymph node metastases
in pT-1 cancers has been confirmed in systematic reviews
and meta-analyses [34–36]. Several authors and societies
recommend the evaluation of tumor budding [37–40], which
underlines its importance. In our study, we also found an
association between high-grade tumor budding and other
adverse factors and outcomes.
Despite investigating another set of 68 cases in addition
to the initial collection, this study is still hampered by a
relatively low case number. Nevertheless, the data of this
studywith a prospective design can serve as a basis for further
investigations. We found a synergistic adverse effect of PAI-1
and tumor budding in uni- and multivariable analyses. This
supports the thesis that stromal degradation facilitates the
migration of detached tumor cells. Because of the association
with the histological type further investigations should focus
on this by comparing collectives with identical UICC stages,
MSI status, and/or locations. Because PAI-1 inhibitors are
already available, additional investigations should address
the question of whether PAI-1 could serve as a target for
anticancer therapy [41].
Competing Interests
The authors declare that they have no competing interests.
Acknowledgments
This work was supported by Sekisui Diagnostics, Stamford,
and by the Hermann-Egger-Stiftung. The authors are grate-
ful to Anna-Maria Bubolz, Katharina Endhardt, and Ines
Lichtmannegger for collecting the fresh tissue sample for the
uPA/PAI-1 analysis.The authors also thankMonikaHallabrin
and Kathrin Ferstl-Blahetek for their excellent technical
assistance.
References
[1] D. Hanahan and R. A.Weinberg, “Hallmarks of cancer: the next
generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[2] W. H. Fridman, F. Pagès, C. Sautes-Fridman, and J. Galon,
“The immune contexture in human tumours: impact on clinical
outcome,” Nature Reviews Cancer, vol. 12, no. 4, pp. 298–306,
2012.
[3] American-Cancer-Society, Cancer Facts & Figures 2016, Amer-
ican Cancer Society, Atlanta, Ga, USA, 2016.
[4] B. Märkl, I. Renk, D. V. Oruzio et al., “Tumour budding, uPA
and PAI-1 are associated with aggressive behaviour in colon
cancer,” Journal of Surgical Oncology, vol. 102, no. 3, pp. 235–241,
2010.
[5] J. R. Jass, Y. Ajioka, J. P. Allen et al., “Assessment of invasive
growth pattern and lymphotic infiltration in colorectal cancer,”
Histopathology, vol. 28, no. 6, pp. 543–548, 1996.
[6] M. Mutoh, N. Niho, M. Komiya et al., “Plasminogen activator
inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation
in Min mice,” Carcinogenesis, vol. 29, no. 4, pp. 824–829, 2008.
[7] P. Minoo, K. Baker, D. Baumhoer, L. Terracciano, A. Lugli,
and I. Zlobec, “Urokinase-type plasminogen activator is a
marker of aggressive phenotype and an independent prognostic
factor in mismatch repair-proficient colorectal cancer,” Human
Pathology, vol. 41, no. 1, pp. 70–78, 2010.
[8] Y. Yamada, T. Arao, K. Matsumoto et al., “Plasma concentra-
tions of VCAM-1 and PAI-1: a predictive biomarker for post-
operative recurrence in colorectal cancer,” Cancer Science, vol.
101, no. 8, pp. 1886–1890, 2010.
[9] N. E. Kushlinskii, E. S. Gershtein, E. A. Korotkova, and V.
V. Prorokov, “Prognostic role of tumor-associated proteases in
colorectal cancer,” Bulletin of Experimental Biology and Medi-
cine, vol. 154, no. 3, pp. 365–369, 2013.
[10] N. M. Hogan, M. R. Joyce, J. M. Murphy et al., “Impact of
Mesenchymal Stem Cell secreted PAI-1 on colon cancer cell
migration and proliferation,” Biochemical and Biophysical Re-
search Communications, vol. 435, no. 4, pp. 574–579, 2013.
[11] E. R. Kim, M. H. Yang, Y. J. Lim et al., “Association between
plasma levels of plasminogen activator inhibitor-1 and colorec-
tal neoplasms,” Gut and Liver, vol. 7, no. 5, pp. 519–523, 2013.
[12] L. Iacoviello, C. Agnoli, A. De Curtis et al., “Type 1 plasminogen
activator inhibitor as a common risk factor for cancer and
ischaemic vascular disease:The EPICOR Study,” BMJOpen, vol.
3, no. 11, article 12, 2013.
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